IE912498A1 - Method for treating viral infections using oxidized¹lipoproteins - Google Patents
Method for treating viral infections using oxidized¹lipoproteinsInfo
- Publication number
- IE912498A1 IE912498A1 IE249891A IE249891A IE912498A1 IE 912498 A1 IE912498 A1 IE 912498A1 IE 249891 A IE249891 A IE 249891A IE 249891 A IE249891 A IE 249891A IE 912498 A1 IE912498 A1 IE 912498A1
- Authority
- IE
- Ireland
- Prior art keywords
- lipoproteins
- blood
- oxidized
- lipoprotein
- patient
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 65
- 230000009385 viral infection Effects 0.000 title claims description 28
- 208000036142 Viral infection Diseases 0.000 title description 11
- 102000004895 Lipoproteins Human genes 0.000 claims abstract description 118
- 108090001030 Lipoproteins Proteins 0.000 claims abstract description 118
- 108010007622 LDL Lipoproteins Proteins 0.000 claims abstract description 28
- 102000007330 LDL Lipoproteins Human genes 0.000 claims abstract description 28
- 201000010099 disease Diseases 0.000 claims abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 11
- 210000004369 blood Anatomy 0.000 claims description 72
- 239000008280 blood Substances 0.000 claims description 72
- 230000001590 oxidative effect Effects 0.000 claims description 24
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 22
- 239000001301 oxygen Substances 0.000 claims description 22
- 229910052760 oxygen Inorganic materials 0.000 claims description 22
- 208000030507 AIDS Diseases 0.000 claims description 21
- 239000007800 oxidant agent Substances 0.000 claims description 16
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 13
- 150000003904 phospholipids Chemical class 0.000 claims description 12
- 150000003626 triacylglycerols Chemical class 0.000 claims description 12
- 150000001840 cholesterol esters Chemical class 0.000 claims description 11
- 102000003992 Peroxidases Human genes 0.000 claims description 10
- 150000001451 organic peroxides Chemical class 0.000 claims description 10
- 108040007629 peroxidase activity proteins Proteins 0.000 claims description 10
- 150000002978 peroxides Chemical class 0.000 claims description 10
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 claims description 10
- 102000003820 Lipoxygenases Human genes 0.000 claims description 8
- 108090000128 Lipoxygenases Proteins 0.000 claims description 8
- LSXWFXONGKSEMY-UHFFFAOYSA-N di-tert-butyl peroxide Chemical compound CC(C)(C)OOC(C)(C)C LSXWFXONGKSEMY-UHFFFAOYSA-N 0.000 claims description 8
- 108010071584 oxidized low density lipoprotein Proteins 0.000 claims description 8
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 6
- 230000003190 augmentative effect Effects 0.000 claims description 6
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 5
- 238000005481 NMR spectroscopy Methods 0.000 claims description 5
- 102000004316 Oxidoreductases Human genes 0.000 claims description 5
- 108090000854 Oxidoreductases Proteins 0.000 claims description 5
- 230000003647 oxidation Effects 0.000 claims description 5
- 238000007254 oxidation reaction Methods 0.000 claims description 5
- 235000019192 riboflavin Nutrition 0.000 claims description 5
- 229960002477 riboflavin Drugs 0.000 claims description 5
- 239000002151 riboflavin Substances 0.000 claims description 5
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 claims description 4
- 230000003859 lipid peroxidation Effects 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 238000011287 therapeutic dose Methods 0.000 claims description 3
- 230000006378 damage Effects 0.000 claims 3
- 238000004458 analytical method Methods 0.000 claims 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 claims 1
- 239000003054 catalyst Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 241000700605 Viruses Species 0.000 abstract description 19
- 241000725303 Human immunodeficiency virus Species 0.000 abstract description 9
- 210000004027 cell Anatomy 0.000 description 45
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 20
- 150000002632 lipids Chemical class 0.000 description 13
- 230000036770 blood supply Effects 0.000 description 10
- 231100000433 cytotoxic Toxicity 0.000 description 6
- 230000001472 cytotoxic effect Effects 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 238000004448 titration Methods 0.000 description 5
- 108010010234 HDL Lipoproteins Proteins 0.000 description 4
- 102000015779 HDL Lipoproteins Human genes 0.000 description 4
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 108010004103 Chylomicrons Proteins 0.000 description 3
- 208000031886 HIV Infections Diseases 0.000 description 3
- 208000037357 HIV infectious disease Diseases 0.000 description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- 108010093096 Immobilized Enzymes Proteins 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 3
- 238000005502 peroxidation Methods 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 108010004942 Chylomicron Remnants Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010046315 IDL Lipoproteins Proteins 0.000 description 2
- 102000011965 Lipoprotein Receptors Human genes 0.000 description 2
- 108010061306 Lipoprotein Receptors Proteins 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 150000002211 flavins Chemical class 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 244000287680 Garcinia dulcis Species 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 108030000116 Riboflavinases Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 231100000230 acceptable toxicity Toxicity 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000005188 flotation Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000007810 virus-infected cell apoptotic process Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55480790A | 1990-07-18 | 1990-07-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IE912498A1 true IE912498A1 (en) | 1992-01-29 |
Family
ID=24214788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE249891A IE912498A1 (en) | 1990-07-18 | 1991-07-17 | Method for treating viral infections using oxidized¹lipoproteins |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP0539506A4 (fi) |
| JP (1) | JPH05508159A (fi) |
| AU (1) | AU8305691A (fi) |
| CA (1) | CA2086921A1 (fi) |
| FI (1) | FI930123A0 (fi) |
| IE (1) | IE912498A1 (fi) |
| PT (1) | PT98373A (fi) |
| WO (1) | WO1992001467A1 (fi) |
| ZA (1) | ZA915639B (fi) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4336641C2 (de) * | 1993-10-22 | 1995-09-07 | Deutsches Rheuma Forschungszen | Verwendung von Superoxid-Dismutase (SOD) zur Behandlung retroviraler Erkrankungen |
| ATE406908T1 (de) * | 2000-10-20 | 2008-09-15 | Hamburger Stiftung Zur Foerder | Oxidierte proteine und deren biologische und therapeutische aktivität sowie diagnostische verwendung über die hemmung der interaktion zwischen oxidierten proteinen und cd36 |
-
1991
- 1991-07-11 CA CA002086921A patent/CA2086921A1/en not_active Abandoned
- 1991-07-11 WO PCT/US1991/004913 patent/WO1992001467A1/en not_active Application Discontinuation
- 1991-07-11 JP JP91513333A patent/JPH05508159A/ja active Pending
- 1991-07-11 EP EP19910914013 patent/EP0539506A4/en not_active Withdrawn
- 1991-07-11 AU AU83056/91A patent/AU8305691A/en not_active Abandoned
- 1991-07-17 IE IE249891A patent/IE912498A1/en unknown
- 1991-07-18 PT PT98373A patent/PT98373A/pt not_active Application Discontinuation
- 1991-07-18 ZA ZA915639A patent/ZA915639B/xx unknown
-
1993
- 1993-01-12 FI FI930123A patent/FI930123A0/fi not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO1992001467A1 (en) | 1992-02-06 |
| EP0539506A4 (en) | 1993-11-24 |
| PT98373A (pt) | 1992-06-30 |
| EP0539506A1 (en) | 1993-05-05 |
| JPH05508159A (ja) | 1993-11-18 |
| CA2086921A1 (en) | 1992-01-19 |
| AU8305691A (en) | 1992-02-18 |
| FI930123A (fi) | 1993-01-12 |
| ZA915639B (en) | 1992-04-29 |
| FI930123A0 (fi) | 1993-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5192264A (en) | Methods and apparatus for treating disease states using oxidized lipoproteins | |
| North et al. | New trends in photobiology: Photosensitizers as virucidal agents | |
| US4915683A (en) | Antiviral method, agents and apparatus | |
| PT1243278E (pt) | Utilização de sangue tendo uma concentração aumentada de óxido nítrico para o fabrico de um medicamento | |
| FR2531857A1 (fr) | Composition injectable pour prolonger la stabilite et la retention de particules enrobees, injectees dans le flux sanguin d'animaux et d'etres humains | |
| US20050238623A1 (en) | Method for treating mammals with modified mammalian blood | |
| JP7111795B2 (ja) | 組合せｈｉｖ治療薬 | |
| Lee et al. | HO-1 and CD39: it takes two to protect the realm | |
| US5366440A (en) | Methods for treating disease states using oxidized lipoproteins in conjunction with chemotherapeutic effector agents | |
| US5217716A (en) | Method for treating viral infections using oxidized lipoproteins | |
| Sieber et al. | Merocyanine-sensitized photoinactivation of enveloped viruses | |
| Wills et al. | The formation of peroxides in tissue lipids and unsaturated fatty acids by irradiation | |
| IE912498A1 (en) | Method for treating viral infections using oxidized¹lipoproteins | |
| US5571082A (en) | Method of producing therapeutic effect upon an organism to reduce the pathologic lymphocyte population | |
| WO1991004744A1 (en) | Methods and apparatus for treating disease states using oxidized lipoproteins | |
| JPS63192718A (ja) | 肝障害抑制剤 | |
| CN104546726A (zh) | 一种自组装核酸纳米管制剂及制备方法和应用 | |
| US11234932B2 (en) | Combination HIV therapeutic | |
| JPS63188391A (ja) | 細菌破壊に及び／又は免疫調節に有効な物質の製造方法並びにこれを使用する方法 | |
| Huang et al. | Lesion-specific suppression of YAP/TAZ by biomimetic nanodrug ameliorates atherosclerosis development | |
| Heijnen et al. | Altered antigen-presentation in the induction of the in-vitro antigen-specific T helper cell function in patients with chronic granulomatous disease. | |
| RU2275921C2 (ru) | Способ лечения хронических диффузных заболеваний печени применением курса внутривенных инфузий растворов гипохлорита натрия | |
| JPH05320043A (ja) | リポポリサッカライド捕捉剤 | |
| JPH05504761A (ja) | 哺乳類のｈｉｖ感染症の治療のための方法及び組成物 | |
| Rakovsky et al. | Application of ozone in medicine |